Neus Salord1, Mercè Gasa2, Mercedes Mayos3, Ana Maria Fortuna-Gutierrez4, Josep Maria Montserrat5, Manuel Sánchez-de-la-Torre6, Antonia Barceló7, Ferran Barbé7, Núria Vilarrasa8, Carmen Monasterio9. 1. Sleep Unit, Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain ; Section of Respiratory Medicine, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Spain ; Universtitat Autonoma de Barcelona, Department of Medicine, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain. 2. Sleep Unit, Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain ; Section of Respiratory Medicine, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Spain. 3. Universtitat Autonoma de Barcelona, Department of Medicine, Barcelona, Spain ; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain ; Sleep Unit, Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 4. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain ; Sleep Unit, Department of Respiratory Medicine, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. 5. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain ; Sleep Unit, Department of Respiratory Medicine, Hospital Clinic de Barcelona, Barcelona, Spain. 6. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain ; Respiratory Diseases Research Unit, Hospital Universitari Arnau de Vilanova, IRB Lleida Lleida, Spain. 7. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain ; Clinic Analysis Service, Hospital Universitari Son Espases, Palma de Mallorca, Spain. 8. Department of Endocrinology and Nutrition, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain ; CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona, Spain. 9. Sleep Unit, Department of Respiratory Medicine, Hospital Universitari de Bellvitge, Hospitalet de Llobregat, Spain ; Section of Respiratory Medicine, Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, Spain ; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Spain.
Abstract
BACKGROUND AND OBJECTIVE: There is compelling evidence that obstructive sleep apnoea (OSA) can affect metabolic syndrome (MetS) and cardiovascular risk, but the intermediate mechanisms through which it occurs have not been well defined. We explored the impact of OSA in morbidly obese patients with MetS on adipokines, pro-inflammatory markers, endothelial dysfunction, and atherosclerosis markers. METHODS: We included 52 morbidly obese patients in an observational study matched for age, gender and central obesity in 3 groups (OSA-MetS, Non-OSA-MetS, and Non OSA-non-MetS). Anthropometrical, blood pressure, and fasting blood measurements were obtained the morning after an overnight polysomnography. VEGF, soluble CD40 ligand (sCD40L), TNF-α, IL-6, leptin, adiponectin, and chemerin were determined in serum by ELISA. OSA was defined as apnea/ hypopnea index ≥ 15 and MetS by NCEP-ATP III. RESULTS: Cases and control subjects did not differ in age, BMI, waist circumference, and gender (43 ± 10 years, 46 ± 5 kg/m(2), 128 ± 10 cm, 71% females). The cases had severe OSA with 47 (32-66) events/h, time spent < 90% SpO2 7% (5%-31%). All groups presented similar serum cytokines, adipokines, VEGF, and sCD40L levels. CONCLUSIONS: In a morbidly obese population with established MetS, the presence of OSA did not determine any differences in the studied mediators when matched by central obesity. Morbidly obese NonOSA-NonMetS had a similar inflammatory, adipokine VEGF, and sCD40L profile as those with established MetS, with or without OSA. Obesity itself could overwhelm the effect of sleep apnea and MetS in the studied biomarkers. CITATION: Salord N; Gasa M; Mayos M; Fortuna-Gutierrez AM; Montserrat JM; Sánchez-de-la-Torre M; Barceló A; Barbé F; Vilarrasa N; Monasterio C. Impact of OSA on biological markers in morbid obesity and metabolic syndrome.
BACKGROUND AND OBJECTIVE: There is compelling evidence that obstructive sleep apnoea (OSA) can affect metabolic syndrome (MetS) and cardiovascular risk, but the intermediate mechanisms through which it occurs have not been well defined. We explored the impact of OSA in morbidly obesepatients with MetS on adipokines, pro-inflammatory markers, endothelial dysfunction, and atherosclerosis markers. METHODS: We included 52 morbidly obesepatients in an observational study matched for age, gender and central obesity in 3 groups (OSA-MetS, Non-OSA-MetS, and Non OSA-non-MetS). Anthropometrical, blood pressure, and fasting blood measurements were obtained the morning after an overnight polysomnography. VEGF, soluble CD40 ligand (sCD40L), TNF-α, IL-6, leptin, adiponectin, and chemerin were determined in serum by ELISA. OSA was defined as apnea/ hypopnea index ≥ 15 and MetS by NCEP-ATP III. RESULTS: Cases and control subjects did not differ in age, BMI, waist circumference, and gender (43 ± 10 years, 46 ± 5 kg/m(2), 128 ± 10 cm, 71% females). The cases had severe OSA with 47 (32-66) events/h, time spent < 90% SpO2 7% (5%-31%). All groups presented similar serum cytokines, adipokines, VEGF, and sCD40L levels. CONCLUSIONS: In a morbidly obese population with established MetS, the presence of OSA did not determine any differences in the studied mediators when matched by central obesity. Morbidly obese NonOSA-NonMetS had a similar inflammatory, adipokine VEGF, and sCD40L profile as those with established MetS, with or without OSA. Obesity itself could overwhelm the effect of sleep apnea and MetS in the studied biomarkers. CITATION: Salord N; Gasa M; Mayos M; Fortuna-Gutierrez AM; Montserrat JM; Sánchez-de-la-Torre M; Barceló A; Barbé F; Vilarrasa N; Monasterio C. Impact of OSA on biological markers in morbid obesity and metabolic syndrome.
Authors: M Fröhlich; A Imhof; G Berg; W L Hutchinson; M B Pepys; H Boeing; R Muche; H Brenner; W Koenig Journal: Diabetes Care Date: 2000-12 Impact factor: 19.112
Authors: Guido A Rosito; Joseph M Massaro; Udo Hoffmann; Frederick L Ruberg; Amir A Mahabadi; Ramachandran S Vasan; Christopher J O'Donnell; Caroline S Fox Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Antony D Karelis; David H St-Pierre; Florence Conus; Remi Rabasa-Lhoret; Eric T Poehlman Journal: J Clin Endocrinol Metab Date: 2004-06 Impact factor: 5.958
Authors: Johanna Weigert; Markus Neumeier; Josef Wanninger; Michael Filarsky; Sabrina Bauer; Reiner Wiest; Stefan Farkas; Marcus N Scherer; Andreas Schäffler; Charalampos Aslanidis; Jürgen Schölmerich; Christa Buechler Journal: Clin Endocrinol (Oxf) Date: 2009-06-24 Impact factor: 3.478
Authors: Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal Journal: Sleep Med Rev Date: 2014-11-28 Impact factor: 11.609
Authors: Graziela De Luca Canto; Camila Pachêco-Pereira; Secil Aydinoz; Paul W Major; Carlos Flores-Mir; David Gozal Journal: J Clin Sleep Med Date: 2015-01-15 Impact factor: 4.062